Boceprevir
- TRADE NAME: Victrelis (Merck)
- INDICATIONS: Chronic hepatitis C
- CLASS: CYP3A4 inhibitor, Direct-acting antiviral, Hepatitis C virus NS3/4A protease inhibitor
- HALF-LIFE: 3 hours
FDA APPROVAL DATE: 05/13/2011
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Alfuzosin, Alprazolam, Amiodarone, Atorvastatin, Bepridil, Bosentan, Brigatinib, Budesonide, Buprenorphine, Cabozantinib, Carbamazepine, Cisapride, Clarithromycin, Colchicine, Copanlisib, Cyclosporine, Dasatinib, Desipramine, Dexamethasone, Digoxin, Dihydroergotamine, Drospirenone, Efavirenz, Ergonovine, Ergotamine, Estradiol, Felodipine, Flecainide, Flibanserin, Fluticasone Propionate, Gefitinib, Itraconazole, Ketoconazole, Lomitapide, Lovastatin, Methadone, Methylergonovine, Midazolam, Midostaurin, Mifepristone, Neratinib, Nicardipine, Nifedipine, Olaparib, Pazopanib, Phenobarbital, Phenytoin, Pimozide, Ponatinib, Posaconazole, Propafenone, Quinidine, Ribociclib, Rifabutin, Rifampin, Ritonavir, Ruxolitinib, Salmeterol, Sildenafil, Simvastatin, Sirolimus, St John's Wort, Tacrolimus, Tadalafil, Trazodone, Triazolam, Vardenafil, Vorapaxar, Voriconazole, Warfarin
PREGNANCY CATEGORY: X
boceprevir is pregnancy category B but must not be used in monotherapy
Must be used in combination with PEG-interferon and ribavirin (see separate entries)
Combination treatment is contra-indicated in pregnant women and men whose female partners are pregnant because of the risks for birth defects and fetal death associated with ribavirin, or in coadministration with drugs that are highly dependent on CYP3A4/5 for clearance, or with potent CYP3A4/5 inducers.
Please login to see the rest of this drug profile
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
